AVAV three-lens brief
Evidence-based stock research on AVAV. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 8% of its 52-week range — deep in the lower band.
- Trading at 8% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 12.2pp over 30 days.
- P/E of 151 — priced for high growth; little margin of safety.
- Analyst mean target $212.20 — 71% above current (23 analysts).
AVAV closed at $124.40 (+0.73%) as of 2026-11-12. Market cap: $6.32B. P/E (trailing) 151.3. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $212.20 — 71% above current (23 analysts).. Concerns: trading at 8% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $480.49M, net income -$5.07M, free cash flow -$25.92M. Watching for: 2026-12-08 earnings release (26 days out).
Why three lenses on AVAV, not one.
A single reasoning model has blind spots it doesn’t know about. We examine AVAV across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/AVAV" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath AVAV brief"></iframe>